|
DE19651443A1
(de)
|
1996-12-11 |
1998-06-18 |
Hoechst Ag |
Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
|
|
WO1998044938A1
(en)
|
1997-04-10 |
1998-10-15 |
University Of Southern California |
Modified proteins which bind extracellular matrix components
|
|
EP1914304A1
(en)
|
1998-10-14 |
2008-04-23 |
Darwin Molecular Corporation |
Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
|
|
JP2002516061A
(ja)
*
|
1997-10-14 |
2002-06-04 |
ダーウィン モレキュラー コーポレイション |
チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
|
|
US6743631B1
(en)
|
1998-03-17 |
2004-06-01 |
North Shore University Hospital Research Corporation |
Use of human serum resistant vector particles and cell lines for human gene therapy
|
|
GB9810999D0
(en)
*
|
1998-05-21 |
1998-07-22 |
Goken Joop |
Materials and methods relating to the expression of genes
|
|
US6490476B1
(en)
|
1999-10-14 |
2002-12-03 |
Cti Pet Systems, Inc. |
Combined PET and X-ray CT tomograph and method for using same
|
|
US6825033B2
(en)
|
2000-03-02 |
2004-11-30 |
University Of Southern California |
Mutated cyclin G1 protein
|
|
US20010046491A1
(en)
|
2000-03-23 |
2001-11-29 |
Valerie Kristoffer C. |
Tumor radiosensitization with mutant thymidine kinase in combination with a prodrug
|
|
US20050130132A1
(en)
|
2002-09-06 |
2005-06-16 |
Day Craig H. |
Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
|
|
US20060216299A1
(en)
|
2002-10-30 |
2006-09-28 |
Rigel Pharmaceuticals, Inc. |
Cell cycle targets and peptides
|
|
US20070178066A1
(en)
|
2003-04-21 |
2007-08-02 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
US20090123428A1
(en)
|
2003-04-21 |
2009-05-14 |
Hall Frederick L |
Pathotropic targeted gene delivery system for cancer and other disorders
|
|
US7815902B2
(en)
|
2003-07-09 |
2010-10-19 |
Henry Ford Health System |
Methods and compositions for cancer therapy using a novel adenovirus
|
|
WO2005007109A2
(en)
|
2003-07-09 |
2005-01-27 |
Henry Ford Health System |
Methods and compositions for cancer therapy using a novel adenovirus
|
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
|
CA2643102A1
(en)
|
2006-03-21 |
2007-09-27 |
The Regents Of The University Of California |
A method for noninvasively and quantitatively monitoring therapeutic and diagnostic transgene expression induced by ex vivo and in vivo gene targeting in organs, tissues and cells
|
|
PT2145189E
(pt)
|
2007-05-08 |
2016-06-16 |
Us Health |
Pseudovírus de papilomavírus para deteção e terapêutica de tumores
|
|
CA2690627C
(en)
|
2007-06-15 |
2014-12-02 |
Genelux Corporation |
Microorganisms for imaging and/or treatment of tumors
|
|
WO2009070636A2
(en)
|
2007-11-27 |
2009-06-04 |
Stanford University |
Engineered cells, imaging reporter gene/probe systems, and methods of imaging
|
|
US20090176260A1
(en)
|
2007-12-04 |
2009-07-09 |
Joseph Ching-Ming Wu |
Double-fusion human embryonic stem cells, methods of making double-fusion human embryonic stem cells, triple-fusion human embryonic stem cells, methods of making triple-fusion human embryonic stem cells, and methods of monitoring double-fusion human embryonic stem cells and triple-fusion human embryonic stem cells
|
|
US9296790B2
(en)
|
2008-10-03 |
2016-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for protein delivery
|
|
EP2376518A4
(en)
|
2008-12-18 |
2013-12-04 |
Avaris Ab |
COMPLEX AND METHOD FOR AMPLIFYING NUCLEAR RELEASE
|
|
KR101032871B1
(ko)
|
2009-07-10 |
2011-05-06 |
주식회사 바이오드 |
비엠피-2와 에이치에스브이-티케이 자살유전자를 동시에 포함하고 발현 할 수 있도록 하는 벡터와 이 벡터가 도입된 자가조절형 줄기세포 치료제
|
|
KR20140027063A
(ko)
|
2010-10-28 |
2014-03-06 |
버지니아 커먼웰스 유니버시티 |
치료와 병용하는 암 영상화: 치료진단
|
|
JP2015505326A
(ja)
|
2012-01-18 |
2015-02-19 |
ニューメディシンズ，インコーポレーテッド |
放射線防護及び放射線誘発性毒性緩和のためのｉｌ−１２
|
|
AU2014236208B2
(en)
|
2013-03-14 |
2018-07-19 |
Genvivo, Inc. |
Thymidine kinase diagnostic assay for gene therapy applications
|
|
JP2018526007A
(ja)
*
|
2015-09-04 |
2018-09-13 |
トカジェン インコーポレーテッド |
２ａペプチドを含む組換えベクター
|
|
WO2017147269A1
(en)
*
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
EP3568474A1
(en)
*
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
WO2018150345A1
(en)
*
|
2017-02-16 |
2018-08-23 |
De Vita Bio Life Sciences |
An expression vector
|
|
EP3592368A1
(en)
*
|
2017-03-08 |
2020-01-15 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
JP7216668B2
(ja)
*
|
2017-05-26 |
2023-02-01 |
エピセントアールエックス，インコーポレイテッド |
導入遺伝子を保持する組換えアデノウイルス
|
|
EP3983444A4
(en)
*
|
2019-06-14 |
2023-10-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against pd-1 and methods of use thereof
|
|
US12071633B2
(en)
*
|
2020-10-13 |
2024-08-27 |
Kriya Therapeutics, Inc. |
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
|
|
CA3235894A1
(en)
|
2021-10-25 |
2023-05-04 |
Brile Chung |
Compositions and methods for therapeutic delivery
|